/Companies

Optimeos-Logo-Web

Princeton, US · Founded 2018 · 10 employees on LinkedIn · 3 known investors

Find your way into Optimeos-Logo-Web

1,054 people in our graph share verified history with the Optimeos-Logo-Web team — schools, employers, funds. One of them is your warm intro.

Kevin Chuunlockedknows Gregory Harriman · together at Robin Hood Ventures (overlapped)
×2knows the team · via Endless Frontier Labs
knows the team · via Siemens Medical Solutions
×8knows the team · via Third Rock Ventures

Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.

Founders & leadership

Optimeos-Logo-Web was founded in 2018 by Robert K. Prud'homme, PhD, Bob Prud'homme, Rob Pagels, and Chet Markwalter.

RK
Robert K. Prud'homme, PhDCo-founder
BPBob Prud'homme
Bob Prud'hommeLeadership (PhD)
RPRob Pagels
Rob PagelsLeadership (PhD)
CMChet Markwalter
Chet MarkwalterLeadership (PhD)Leadership (PhD) at Optimeos
SHShahram Hejazi, PhD
Shahram Hejazi, PhDFounder and CEO2019–2026Shahram Hejazi holds a Ph.D. in electrical and computer engineering with an emphasis in biophysics from SUNY Buffalo and has held R&D and executive leadership roles in medical imaging, diagnostics, and life sciences at companies including IBM, Kodak, Siemens, and Zargis Medical, where he was CEO; he founded Optimeos Life Sciences, a gene therapy platform company spun from Princeton University, where he is also a professor.
SHShahram Hejazi
Shahram HejaziLeadership (PhD)Shahram Hejazi holds a Ph.D. in electrical and computer engineering with an emphasis in biophysics from SUNY Buffalo and has held leadership roles at Kodak's Life Sciences Division (2004–2008), served as CEO of Zargis Medical (an FDA-approved AI diagnostic company), and held strategic business development positions at Siemens before founding Optimeos Life Sciences, a gene therapy platform company spun out of Princeton University, where he is also a professor of entrepreneurship.
GHGregory Harriman
Gregory HarrimanLeadership (MD)Gregory Harriman is Managing Director at Optimeos, a biotech company developing nanoparticle-based drug delivery platforms for biologics. He has background in pharmaceutical R&D, business development, and venture investing.
MEMark Esposito
Mark EspositoLeadership (PhD)Mark Esposito holds a PhD and leads Optimeos, which develops a nanoparticle-based drug delivery platform for complex biologics including mRNA, DNA, peptides, and proteins. He has also worked as a consultant to biotech and pharmaceutical companies.

Board

JSJason Smith
Jason SmithLeadership (PhD)Partner at Anzu Partners
BD
Benjamin DoranzBoard director
JS
Jason Smith, PhDBoard director

Investors · 3

Reported raises · per SEC filings

Form D private placements

$4.4M disclosed across 4 rounds · 2020–2026

▶$1MraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason SmithDirector
  • Shahram HejaziExecutive Officer, Director
  • Robert K Prud'hommeDirector
  • Benjamin DoranzDirector
Offering amount
$2M
Amount sold
$1M
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedNov 2024 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin DoranzDirector
  • Shahram Hejazi, PhDExecutive Officer, Director
  • Jason Smith, PhDDirector
  • Robert K. Prud'homme, PhDDirector
Offering amount
$5M
Amount sold
$2.9M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$175KraisedJun 2021 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason Smith, PhDDirector
  • Robert K Prud'homme, PhDDirector
  • Shahram Hejazi, PhDExecutive Officer, Director
Offering amount
$300K
Amount sold
$175K
First sale
May 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$270KraisedAug 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert Prud'homme, PhDDirector
  • Jason Smith, PhDDirector
  • Shahram Hejazi, PhDExecutive Officer, Director
Offering amount
$400K
Amount sold
$270K
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Optimeos went on to found or lead other companies.

Non-dilutive funding · 5 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2023$1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$287.7K
National Science FoundationPhase ISTTR2021$256K
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$255.4K
National Science FoundationPhase ISTTR2019$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Optimeos-Logo-Web do?
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
Who founded Optimeos-Logo-Web?
Optimeos-Logo-Web was founded by Robert K. Prud'homme, PhD, Bob Prud'homme, Rob Pagels, Chet Markwalter in 2018.
Who are Optimeos-Logo-Web's investors?
Optimeos-Logo-Web's investors include 7G BioVentures, Anzu Partners, Hatch BioFund.
How much funding has Optimeos-Logo-Web raised?
Optimeos-Logo-Web has disclosed $4.4M raised across 4 rounds.
Where is Optimeos-Logo-Web headquartered?
Optimeos-Logo-Web is headquartered in Princeton, US.